Search

10X Genomics Inc (Class A)

Закрыт

СекторЗдравоохранение

46.37 -3.5

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

46.01

Макс.

47.26

Ключевые показатели

By Trading Economics

Доход

2.8M

-13M

Продажи

-15M

151M

Прибыль на акцию

0.07

Рентабельность продаж

-8.93

Сотрудники

1,178

EBITDA

19M

-937K

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

-13.08% downside

Дивиденды

By Acuity

Следующий отчет о доходах

6 авг. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

2.7B

5.5B

Предыдущая цена открытия

49.87

Предыдущая цена закрытия

46.37

Новостные настроения

By Acuity

100%

0%

324 / 340 Рейтинг в Healthcare

10X Genomics Inc (Class A) График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 июл. 2026 г., 16:26 UTC

10X Genomics Inc shares declined during Friday's session, hitting a session low before a slight recovery. The stock remains above its 20-day moving average.

23 июл. 2026 г., 23:26 UTC

Correlated Moves

10X Genomics Inc shares declined in after-market trading, mirroring a broader market trend. The stock remains near the upper end of its one-month range.

22 июл. 2026 г., 19:51 UTC

Correlated Moves

10X Genomics Inc reports a first-quarter net loss of -$34 million, with revenue falling to $47 million, as shares trade lower amid broader market declines.

21 июл. 2026 г., 19:53 UTC

Correlated Moves

Positive investor sentiment drives 10X Genomics Inc higher amid a broader market recovery, reflecting gains since Monday's close and aligning with small-cap stock interest.

20 июл. 2026 г., 19:16 UTC

News
Correlated Moves

10X Genomics Inc. shares are lower as a report cites only 1.1% annual sales growth and ineffective growth strategies amid a declining Life Sciences Tools sector.

Сравнение c конкурентами

Изменение цены

10X Genomics Inc (Class A) Прогноз

Целевая цена

By TipRanks

-13.08% падение

Прогноз на 12 месяцев

Средняя 40.22 USD  -13.08%

Максимум 50 USD

Минимум 23 USD

Основано на мнении 11 аналитиков Wall Street, спрогнозировавших целевые цены для 10X Genomics Inc (Class A) на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

11 ratings

3

Покупка

8

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
help-icon Live chat